» Articles » PMID: 16532038

Mutations of the Tumor Suppressor Gene SOCS-1 in Classical Hodgkin Lymphoma Are Frequent and Associated with Nuclear Phospho-STAT5 Accumulation

Overview
Journal Oncogene
Date 2006 Mar 15
PMID 16532038
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

The suppressors of cytokine signaling (SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma (PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P. For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma (HL)-derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue (P < 0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.

Citing Articles

B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.

Weniger M, Seifert M, Kuppers R Methods Mol Biol. 2024; 2865:1-30.

PMID: 39424718 DOI: 10.1007/978-1-0716-4188-0_1.


Histopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Ding Y, Jaffe E J Clin Transl Pathol. 2024; 4(2):61-69.

PMID: 39070246 PMC: 11271245. DOI: 10.14218/jctp.2024.00015.


Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.

Savelli C, Bisio M, Legato L, Fasano F, Santambrogio E, Nicolosi M Cancers (Basel). 2024; 16(10).

PMID: 38791909 PMC: 11120540. DOI: 10.3390/cancers16101830.


SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity.

Ilangumaran S, Gui Y, Shukla A, Ramanathan S Front Immunol. 2024; 15:1362224.

PMID: 38415248 PMC: 10897024. DOI: 10.3389/fimmu.2024.1362224.


Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT.

Fernandez S, Cereceda L, Diaz E, Figueroa S, Reguera L, Menendez V EJHaem. 2024; 5(1):70-75.

PMID: 38406538 PMC: 10887323. DOI: 10.1002/jha2.826.